Open AccessA formalization of one of the main claims of “Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention” by Fragoulakis et al. 20191
Author(s) -
George P. Patrinos
Publication year - 2022
Publication title -
data science
Language(s) - English
Resource type - Journals
eISSN - 2451-8492
pISSN - 2451-8484
DOI - 10.3233/ds-210042
Subject(s) - clopidogrel , conventional pci , pharmacogenomics , medicine , percutaneous coronary intervention , context (archaeology) , class (philosophy) , intensive care medicine , intervention (counseling) , pharmacology , computer science , aspirin , myocardial infarction , psychiatry , paleontology , artificial intelligence , biology
Fragoulakis et al. claimed in previous work that pharmacogenomics-guided clopidogrel strategy represents a cost-effective treatment for patients undergoing PCI. We present here a formalization of that claim, stating that all things of class “pharmacogenomics guided clopidogrel therapy” that are in the context of a thing of class “patient undergoing PCI” generally have a relation of type “enables” to a thing of class “cost-effective treatment” in the same context.